The ANGEL1 Knockout HAP1 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population of the HAP1 cell line, carrying targeted disruption of the human ANGEL1 gene. This heterozygous gene knockout pool serves as a loss-of-function model to dissect the contributions of ANGEL1 to mRNA biology. The polyclonal format offers a practical alternative to clonal isolation, yielding a diverse edited cell collection suitable for robust functional analyses without assuming monoclonality or biallelic inactivation.
HAP1 is a suspension-adapted, near-haploid cell line derived from the chronic myeloid leukemia line KBM-7. Its predominantly haploid karyotype enables unmasking of recessive phenotypes upon single-allele gene disruption, making it a preferred model for haploid genetic screens. The line retains many features of myeloid leukemia cells while providing simplified genetics for systematic investigation of gene function in cancer, signal transduction, and drug response.
ANGEL1 functions as the catalytic deadenylase within the CCR4-NOT complex, a multimeric assembly central to eukaryotic mRNA turnover. In this complex, ANGEL1 associates with the scaffold subunit CNOT1 and the deadenylase CNOT7 to excise the 3′ poly(A) tail, the initial and rate-limiting step in the major mRNA decay pathway. Poly(A) removal by ANGEL1 exposes the mRNA to decapping enzymes, which then permit processive 5′-3′ exonucleolytic digestion by XRN1. ANGEL1 acts downstream of the PAN2-PAN3 deadenylase complex to complete poly(A) tail shortening. While specific upstream regulators of ANGEL1 remain to be characterized, its activity broadly governs the stability of numerous transcripts, placing it at a critical node in post-transcriptional gene regulation with implications for cancer-related mRNA processing defects.
In this HAP1 knockout system, disruption of ANGEL1 abrogates its catalytic function, leading to accumulation of deadenylated cellular mRNAs and widespread changes in gene expression. The haploid context ensures that loss-of-function effects are directly reflected at the phenotypic level, facilitating clean interpretation of experimental data. Consequently, these polyclonal knockout cells enable precise inquiry into how ANGEL1-dependent deadenylation controls transcriptome dynamics and how its misregulation contributes to oncogenic gene expression programs.
These cells are suitable for diverse experimental strategies, including RNA stability (actinomycin D chase) assays to measure transcript half-lives, quantitative reverse-transcription PCR, and RNA-sequencing for transcriptome-wide analysis. Protein?CRNA interaction methods such as ribosome profiling can evaluate translational consequences of mRNA stabilization, while polysome profiling distinguishes between translational and decay regulation. In vitro deadenylation assays using cell lysates can directly assess CCR4-NOT activity, and co-immunoprecipitation studies may examine ANGEL1 interaction with CNOT1, CNOT7, or other complex members. These applications support functional genomics studies, mRNA decay pathway mapping, and cancer biology research. For more information, please contact Ascent Research.
